FDA nixes melanoma use for PegIntron

Despite an advisory panel's recommendation, the FDA has declined to approve a new use for Schering-Plough's PegIntron, saying that it has "outstanding concerns" about a melanoma indication for the drug. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.